← All Posts
PCR
Pacira BioSciences, Inc.
June 10, 2026
•
Author: Phil Ratcliff
•
PCRX
| Item |
Proposal |
Vote |
| 1 |
Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. |
|
| 1A |
Christopher J. Christie |
✓ For(10.503)
|
| 1B |
Samit Hirawat |
✓ For(10.503)
|
| 1C |
Tom Wiggans |
✓ For(10.503)
|
| 1D |
Oliver Benton Curtis III |
Withhold(10.503)
|
| 1E |
Eric de Armas |
Withhold(10.503)
|
| 1F |
Christopher Dennis |
Withhold(10.503)
|
| 2 |
Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. |
✓ For(10.503)
|
| 3 |
Approval, on an advisory basis, of the compensation of our named executive officers. |
✓ For(10.503)
|
| 4 |
Approval of our Amended and Restated 2011 Stock Incentive Plan. |
✓ For(10.503)
|
| 5 |
Approval of our Amended and Restated 2014 Employee Stock Purchase Plan. |
✓ For(10.503)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial